Incyte (NASDAQ:INCY) Price Target Cut to $127.00 by Analysts at Wells Fargo & Company

Key Points

• Wells Fargo lowered Incyte’s price target to $127 from $128 while maintaining an “equal weight” rating, implying approximately 4.9% upside from the reported share price.
• Analyst sentiment remains mixed: Incyte has a consensus “Hold” rating and an average price target of $132.90, with 12 Buy, 12 Hold, and 1 Sell recommendation.
• Shares rose 3.6% to $121.06 after the company reported quarterly revenue of $1.56 billion, up 14% year over year and above expectations, despite a $3.60 per-share loss tied largely to a major acquisition-related research charge.

Incyte (NASDAQ:INCY - Get Free Report) had its price target reduced by analysts at Wells Fargo & Company from $128.00 to $127.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an "equal weight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's price objective would indicate a potential upside of 4.91% from the company's current price.

Other equities research analysts also recently issued reports about the stock. Royal Bank Of Canada lifted their price target on shares of Incyte from $114.00 to $117.00 and gave the company a "sector perform" rating in a research report on Friday. Canaccord Genuity Group initiated coverage on Incyte in a research note on Thursday, August 20th. They issued a "buy" rating and a $152.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating on shares of Incyte in a report on Tuesday. Guggenheim boosted their target price on Incyte from $136.00 to $150.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Finally, Citigroup reissued a "buy" rating on shares of Incyte in a report on Monday, August 3rd. Twelve analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $132.90.

Incyte Trading Up 3.6%

Shares of NASDAQ:INCY traded up $4.25 during midday trading on Friday, hitting $121.06. The stock had a trading volume of 1,076,579 shares, compared to its average volume of 1,730,010. Incyte has a 1 year low of $89.25 and a 1 year high of $132.60. The stock has a 50 day moving average price of $120.62 and a two-hundred day moving average price of $108.07. The company has a market capitalization of $24.54 billion, a PE ratio of 15.42, a P/E/G ratio of 4.83 and a beta of 0.74.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating analysts' consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The company had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same quarter in the previous year, the company earned $2.26 EPS. The firm's revenue for the quarter was up 14.0% compared to the same quarter last year. As a group, equities analysts expect that Incyte will post 1.97 EPS for the current year.

Insiders Place Their Bets

In other Incyte news, insider Pablo Cagnoni sold 10,801 shares of Incyte stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the sale, the insider owned 183,200 shares in the company, valued at $23,002,592. The trade was a 5.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 16.20% of the company's stock.

Institutional Investors Weigh In On Incyte

Several large investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Incyte in the second quarter valued at approximately $2,044,189,000. Legal & General Group Plc bought a new stake in shares of Incyte during the second quarter valued at approximately $182,054,000. Caisse de depot et placement du Quebec bought a new stake in shares of Incyte during the second quarter valued at approximately $155,360,000. Deutsche Bank AG acquired a new position in shares of Incyte during the second quarter worth approximately $143,172,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Incyte during the second quarter worth approximately $110,279,000. Institutional investors and hedge funds own 96.97% of the company's stock.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Barclays raised its price target on Incyte from $139 to $143 and maintained an “overweight” rating, implying substantial upside from recent levels. Barclays analyst rating
• Positive Sentiment: Third-quarter revenue beat expectations. Incyte reported $1.56 billion in total revenue, up 14% year over year and above the $1.46 billion analyst consensus. Product demand was broad-based: Jakafi and Jakafi XR sales rose 4% to $827 million, Opzelura sales increased 36% to $255 million, and hematology and oncology portfolio sales climbed 38% to $235 million. Incyte Q3 results
• Positive Sentiment: Management increased its 2026 outlook. Full-year net-sales guidance was raised to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion previously, while Opzelura guidance was lifted to $1.10 billion-$1.12 billion. The stronger outlook reinforces expectations for continued commercial momentum. Incyte raises 2026 guidance
• Neutral Sentiment: Analyst views remain mixed. One Seeking Alpha analysis upgraded Incyte to “hold,” arguing that recent ESMO-related developments had largely closed the valuation gap, while other analysts—including Barclays and Guggenheim—remain constructive. Incyte valuation analysis
• Negative Sentiment: Incyte posted a quarterly loss after recording a $1.23 billion in-process research and development charge tied to its Vega Therapeutics acquisition. The company reported a loss of $3.60 per share, although this was narrower than analysts expected and largely reflected the acquisition accounting charge. Incyte Q3 acquisition charge

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.